As the economic implications of the pandemic redefine the parameters of payer decision-making, the need for agile strategic insight – and greater collaboration – has only intensified. Pharma finds itself at the brink of great change. But in a US market increasingly driven by extreme unknowns, one thing has become crystal clear: deep understanding of […]
